Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 9, 2008, Pages 929-936

  Zhu, Xiaodong ^a   Leaw, Jiin ^a   Gu, Weilie ^a   Qian, Yiying ^b   Du, Hongyu ^c   Wang, Biyun ^a   Hong, Xiaonan ^a   Yin, Jiliang ^a  

^a FUDAN UNIVERSITY   (China)

^b Suzou University   (China)

^c Department of Hematology and Oncology   (China)

Author keywords

Adenocarcinoma; Antineoplastic combined chemotherapy protocols; Epirubicin; Fluorouracil; Stomach neoplasms; Therapeutic use

Indexed keywords

EPIRUBICIN; FLUOROURACIL; OXALIPLATIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIMB DISEASE; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 49649121540     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0376-4     Document Type: Article

References (28)

1. SE Al-Batran A Atmaca S Hegewisch-Becker D Jaeger S Hahnfeld MJ Rummel G Seipelt A Rost J Orth A Knuth E Jaeger 2004 Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer J Clin Oncol 22 658 663
2. T André A Bensmaine C Louvet E Francois V Lucas F Desseigne K Beerblock O Bouche E Carola Y Merrouche F Morvan G Dupont-Andre A de Gramont 1999 Multicenter phase II study of bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin regimen (FOLFOX 3/4) J Clin Oncol 17 3560 3568
3. A Bamias ME Hill D Cunningham AR Norman FY Ahmed A Webb M Watson AS Hill MC Nicolson ME O'Brien TC Evans V Nicolson 1996 Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival Cancer 77 1978 1985
4. O Bouché M Ychou P Burtin L Bedenne M Ducreux G Lebreton J Baulieux B Nordlinger C Martin JF Seitz JM Tigaud E Echinard N Stremsdoerfer C Milan P Rougier 2005 Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) Ann Oncol 16 1488 1497
5. Cunningham D, Rao S, Starling N, Iveson T,Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2006) Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. vol 24, no. 18S (June 20 Supplement), LBA4017
6. F De Vita M Orditura E Matano R Bianco C Carlomagno S Infusino V Damiano E Simeone MR Diadema E Lieto P Castellano S Pepe S De Placido G Galizia N Di Martino F Ciardiello G Catalano AR Bianco 2005 A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients Br J Cancer 92 1644 1649
7. JM Extra M Espie F Calvo C Ferme L Mignot M Marty 1990 Phase I study of oxaliplatin in patients with advanced cancer Cancer Chemother Pharmacol 25 299 303
8. M Findlay D Cunningham A Norman J Mansi M Nicolson T Hickish V Nicolson A Nash N Sacks H Ford 1994 A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF) Ann Oncol 5 609 616
9. DY Kim JH Kim SH Lee TY Kim DS Heo YJ Bang NK Kim 2003 Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer Ann Oncol 14 383 387
10. YH Kim SW Shin BS Kim JH Kim JG Kim YJ Mok CS Kim HS Rhyu JH Hyun JS Kim 1999 Paditaxel, 5-fluorouracil and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma Cancer 85 295 301
11. F Lordick S Lorenzen J Stollfuss U Vehling-Kaiser F Kullmann M Hentrich R Zumschlinge H Dietzfelbinger J Thoedtmann M Hennig T Seroneit R Bredenkamp J Duyster C Peschel 2005 Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer Br J Cancer 93 190 194
12. C Louvet T Andre JM Tigaud E Gamelin JY Douillard R Brunet E Francois JH Jacob D Levoir A Taamma P Rougier E Cvitkovic A de Gramont 2002 Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 4543 4548
13. MoiseyenkoVM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, BoniC, Anelli A, Yver AJ, Van Cutsem E (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 24:abstr 4002
14. A Ohtsu Y Shimada K Shirao N Boku I Hyodo H Saito N Yamamichi Y Miyata N Ikeda S Yamamoto H Fukuda S Yoshida 2003 Randomized phase III trial of fluorouracil alone v fluorouracil plus cisplatin v uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54 59
15. DM Parkin 1998 Epidemiology of cancer global patterns and trends Toxicol Lett 102-103 227 234
16. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108
17. L Pendyala P Creaven 1993 In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin Cancer Res 53 5970 5976
18. E Raymond C Buquet-Fagot S Djelloul J Mester E Cvitkovic P Allain C Louvet C Gespach 1997 Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers Anticancer Drugs 8 876 885
19. P Ross M Nicolson D Cunningham J Valle M Seymour P Harper T Price H Anderson T Iveson T Hickish F Lofts A Norman 2002 Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 1996 2004
20. AD Roth R Maibach G Martinelli N Fazio MS Aapro O Pagani R Morant MM Borner R Herrmann H Honegger F Cavalli P Alberto M Castiglione A Goldhirsch 2000 Docetaxel (Taxotere)-/cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO) Ann Oncol 11 301 306
21. Rubin P, Williams JP, Okunieff P, Rosenblatt JD, Sitzmann JV (2001) Statement of the clinical oncologic problem. In: Rubin P, Williams JP (eds) Clinical oncology A multidisciplinary approach for physicians and students, 8th edn. Elsevier, New York, pp 1-32
22. A Trotti R Byhardt J Stetz C Gwede B Corn K Fu L Gunderson B McCormick M Morrisintegral T Rich W Shipley W Curran 2000 Common toxicity criteria:version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy Int J Radiat Oncol Biol Phys 47 13 47
23. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem M Planker JG Santos P Piedbois B Paillot H Bodenstein HJ Schmoll H Bleiberg B Nordlinger ML Couvreur B Baron JA Wils 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin v etoposide, leucovorin, and fluorouracil v infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657
24. JS Waters A Norman D Cunningham JH Scarffe A Webb P Harper JK Joffe M Mackean J Mansi M Leahy A Hill J Oates S Rao M Nicolson T Hickish 1999 Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 80 269 272
25. A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe M Hughes J Mansi M Findlay A Hill J Oates M Nicolson T Hickish M O'Brien T Iveson M Watson C Underhill A Wardley M Meehan 1997 Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261 267
26. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. Geneva, Switzerland, World Health Organization, WHO Offset Publication No. 48
27. L Yang 2006 Incidence and mortality of gastric cancer in China World J Gastroenterol 12 17 20
28. A Zaniboni S Barni R Labianca G Marini G Pancera G Giaccon E Piazza A Signaroldi W Legnani G Luporini 1995 Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report Cancer 76 1694 1699